Canada Invests Nearly $3 Million in Psilocybin-Assisted Psychotherapy Research

LOS ANGELES- The Government of Canada, through the Canadian Institutes of Health Research (CIHR), has committed nearly $3 million to fund three clinical trials investigating psilocybin-assisted psychotherapy as a treatment for various mental health and substance use disorders.

Funded Clinical Trials:

1. Psilocybin-Assisted Existential, Attachment, and Relational Therapy for Advanced Cancer Patients: Led by Dr. Sarah Hales at the University of Toronto, this trial focuses on alleviating end-of-life psychological distress in patients with advanced-stage cancer.

2. Mechanisms Supporting Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder: Conducted by Dr. Leah Mayo at the University of Calgary, this study examines the safety and efficacy of psilocybin in treating alcohol use disorder.

3. Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Under the guidance of Dr. Joshua Rosenblat at the University of Toronto, this randomized Phase II clinical trial compares the effects of one versus two doses of psilocybin in individuals with treatment-resistant depression.

These trials aim to assess the safety and effectiveness of combining psilocybin—a naturally occurring psychedelic compound found in certain mushroom species—with psychotherapy to treat specific mental health and substance use disorders.

This investment aligns with the Canadian Drugs and Substances Strategy, reflecting the government’s evidence-based approach to addressing substance use and mental health challenges. The outcomes of these studies are anticipated to inform future policies and treatment options in Canada.